ClinicaliQ Trial Snapshot
- Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection — Recruiting • Phase I • Oncology • NCT05413850.
- What is being tested: (177Lu) rhPSMA-10.1 is a radioligand therapy targeting PSMA-expressing tumours in metastatic castrate-resistant prostate cancer, with evaluation of optimal dosing, safety profile, radiation dosimetry and anti-tumour efficacy.
- Patient eligibility overview: The trial enrolls participants with PSMA-expressing metastatic castrate-resistant prostate cancer who have progressed despite androgen deprivation therapy, representing an advanced disease population with limited treatment options.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
To determine the dose, safety, radiation dosimetry and efficacy of 177Lu-rhPSMA-10.1 in participants with PSMA-expressing metastatic castrate resistant prostate cancer.
Eligibility Snapshot
- : 1. Male subjects, 18 years of age or older with histologically confirmed adenocarcinoma of the prostate. 2. Serum testosterone levels
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.